Recent news highlights UTMD's earnings declines in Q1 and Q2 2026 due to customer losses and litigation costs, alongside announcements of cash dividends and analyst coverage.

• Utah Medical's Q2 2026 earnings declined year-over-year due to customer losses [N1].
• The company announced a cash dividend in June 2026 [N2].
• Q1 2026 earnings fell year-over-year due to elevated litigation costs [N5].
• Q4 2025 earnings were negatively impacted by OEM sales decline [N8].
• Analyst blogs and reports in mid-2026 highlighted UTMD among other companies [N3][N4][N6].
• Ex-dividend date was noted in March 2026 [N7].

UTMD benefits from a broad product portfolio with strong clinician recognition and a global distribution network including direct sales and numerous independent distributors. Its manufacturing expertise and ISO certification enable it to serve OEM customers and diversify revenue streams. The company's history of acquisitions has expanded its product offerings and geographic reach. Strong liquidity and a history of returning capital to shareholders through dividends and share repurchases reflect financial discipline. Continued product development efforts and clinician-driven innovation support ongoing relevance in specialized medical device markets.

UTMD faces risks from declining sales to key customers, as evidenced by recent earnings declines due to customer losses and OEM sales reductions. Litigation costs have also impacted profitability. The company's competitive position may weaken if hospital purchasing decisions increasingly prioritize price over clinical outcomes, limiting access to clinicians who influence device selection. Foreign currency fluctuations and reciprocal tariffs affect international sales and cost competitiveness. Dependence on a limited number of distributors and customers in certain regions adds concentration risk. The company's ability to retain skilled employees and successfully develop new products is critical but uncertain.

UTMD's competitive advantage lies in its focus on producing medical devices that offer significant incremental improvements in patient safety, clinical outcomes, and cost-effectiveness compared to substitutes. The company's long-standing relationships with clinicians, established brand recognition, and integration of diverse engineering disciplines contribute to product differentiation. Its ISO 13485 certification and manufacturing capabilities support OEM subcontracting, enhancing utilization and margins. However, the company faces competition from multiple competitors for each device type and challenges from restricted access to hospital clinicians and administrative purchasing decisions focused on price rather than clinical outcomes.

• Customer Concentration and Sales Declines: Significant sales declines have occurred due to loss of major customers, including a sharp reduction in sales to PendoTECH, previously a large OEM customer.
• Litigation Costs: Elevated litigation costs have negatively impacted earnings, as reported in recent quarters.
• Competitive and Market Access Risks: Restricted access to hospital clinicians and increased administrative focus on price rather than clinical outcomes may weaken UTMD's competitive position.
• Foreign Currency and Tariff Exposure: A substantial portion of international sales are invoiced in foreign currencies, exposing UTMD to exchange rate fluctuations and reciprocal tariffs that can affect sales and costs.
• Product Development and Regulatory Risks: New product development projects face risks of not achieving market acceptance or regulatory approval, and competition may introduce superior solutions.
• Employee Retention: The company's success depends on retaining skilled and experienced employees; loss of key personnel could affect product quality and innovation.

• Utah Medical Products, Inc. (UTMD) produces high quality, cost-effective medical devices differentiated by safety and improved patient outcomes [S1].
• UTMD's success depends on recognizing clinician and patient needs, rapid design or acquisition of economical solutions with regulatory approval, reliable production, and sales through direct channels or partnerships [S1].
• The company integrates engineering disciplines including electronics, software, mechanical assembly, plastics processing, and instrumentation to create differentiated devices that improve patient safety, clinical outcomes, and total cost of care [S1].
• UTMD markets a broad range of medical devices primarily used in neonatal intensive care units (NICU), labor and delivery (L&D) departments, and women's health centers, as well as outpatient clinics and physician offices [S1].
• The company sells domestically directly to clinical end-users or stocking distributors and manufactures components and finished devices on a subcontract basis for other companies [S1].
• Outside the U.S., UTMD sells directly to end-users in Canada, UK, France, Ireland, Australia, and New Zealand, and through approximately 200 independent distributors globally [S1].
• UTMD has four OUS facilities in England, Australia, Canada, and Ireland, which provide marketing, regulatory, and manufacturing advantages [S17].
• In 2025, 41% of consolidated revenues were from outside the U.S., with 72% of OUS sales invoiced in foreign currencies, exposing the company to FX risks [S17].
• The company has a history of acquisitions that expanded product lines and distribution channels, including Columbia Medical, Gesco International neonatal products, Abcorp, and Femcare Holdings [S3].
• Sales from acquired product lines comprised 57% of consolidated 2025 sales [S3].
• UTMD's largest OEM customer, PendoTECH, accounted for 22% of sales in 2022 but declined to 1% in 2025 as UTMD stopped accepting orders from them [S18].
• The company competes primarily on improved patient safety and device reliability, with competitors offering substitute but not equivalent devices [S1].
• UTMD faces challenges from restricted access to U.S. hospital clinicians and increased administrative focus on price rather than clinical outcomes, which may weaken competitive position [S1].
• The company maintains ISO 13485 certification, supporting its manufacturing and OEM subcontracting business [S5].
• UTMD's product development focuses on augmenting existing devices, neonatal intensive care, cervical/uterine disease procedures, labor and delivery, biopharmaceutical pressure sensors, and OEM customer projects [S13].
• Internal product development expenses were approximately 2% of sales in 2026 [S13].
• As of December 31, 2025, UTMD had 140 full-time employees worldwide, with an average tenure of 17 years in Utah and Ireland, supporting high-quality device production [S13].
• The company owns seven unexpired U.S. patents and 33 registered trademarks, with trademarks considered more valuable due to brand recognition [S20].
• UTMD's liquidity as of June 30, 2026 included $87.5 million in cash and equivalents, current assets of $100.6 million, current liabilities of $2.07 million, resulting in a current ratio of 48.62 and cash ratio of 42.28, indicating strong short-term liquidity [S2].
• Net income for the quarter ended June 30, 2026 was $2.686 million with basic and diluted EPS of $0.84 [S2].
• The company has returned $156 million in share repurchases and $90 million in dividends since 1992 [S3].
• Recent news highlights include Q2 2026 earnings down year-over-year due to customer losses, Q1 2026 earnings fall due to elevated litigation costs, and Q4 2025 earnings hurt by OEM decline [N1][N5][N8].
• UTMD announced a cash dividend in June 2026 [N2].